Constipation is a disorder in which there is trouble in clearing the bowels, usually linked with hardened faeces. Constipation is interpreted differently by physicians and patients and is common medical condition among elderly and women. Constipation most commonly occurs when waste or stool moves too slowly through the digestive tract or cannot be eliminated effectively from the rectum, which may cause the stool to become hard and dry. Common symptoms of constipation are having lumpy or hard stools, lower abdominal discomfort, straining to have bowel movements, feeling as though there's a blockage in your rectum that prevents bowel movements, infrequent bowel movements, needing help to empty your rectum. Being an older adult, being dehydrated, little or no physical activity, having diet that's low in fiber, and having mental conditions such as depression or eating disorder can contribute to constipation.
Obtain Report Details: http://www.transparencymarketresearch.com/constipation-treatment-market.html
Constipation treatment normally starts with lifestyle and diet changes meant to increase the speed at which stool moves through your intestines, if it doesn’t help doctors or physicians recommend medications or surgery. Lifestyle and diet change include increase in fiber intake, physical activities such as exercise to increase muscle activities in intestines and take sufficient time in bathroom, allowing enough time to have a bowel movement without felling rushed. Rising prescription opioid consumption, growing ageing population, rising healthcare expenditure, launch of targeted medicines, and growing awareness likely to drive the constipation treatment market in the forecast period. According to National Center for Biotechnology Information, over 4 million people in the United States have frequent constipation, corresponding to a prevalence of about 2 percent. Constipation was the most common digestive complaint in the United States, outnumbering all other chronic digestive conditions.
The constipation treatment market has been segmented by type, by treatment options, by method of administration, by distribution channel and by geography. In terms of type, the constipation treatment market has been categorized into chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC). The number of patients suffering from opioid induced constipation is increasing across the globe. Close to 100 Mn U.S. patients in 2013 were suffering from OIC, according to the American Academy of Pain Medicine. Based on treatment options, the constipation treatment market has been categorized into pharmacological treatment and non pharmacological treatment. Further, pharmacological treatment is segmented into bulk-forming agents, stool softeners and emollients, osmotic agents, stimulants, chloride channel activators and others. Based on method of administration, the constipation treatment market is categorized into oral and parenteral (subcutaneous injection). And based on distribution channel, constipation treatment market is categorized into drug store, independent pharmacies and hospital pharmacies.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16442
Geographically, constipation treatment market has been categorized in five regions, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America was observed to be the largest constipation treatment market owing to the large percentage of population suffers from constipation. At the moment, North America dominates in terms of opioid consumption. According to the American Society of Interventional Pain Physicians, the U.S. alone consumes close to 80% of the global supply of opioids. Europe was observed to be the second largest market in the high acuity information system, the high prevalence rates, economic cost and adverse implications on the quality of life and health state likely to drive the market in Europe. The major factor that would drive the market in Asia Pacific include the acceptance and demand for high end medical infrastructure in the region. China, Japan and India are the most developing countries in the region and hence would fuel the market growth for constipation treatment market. According to Abbott Gut-Health Survey, 14% of people in urban India suffer from chronic constipation. South American countries such as Brazil and Mexico are the regions that have significant potential for growth due to evolving medical structure, and high disposable income.
The major players operating in this market include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., Cosmo Pharmaceuticals, Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., and Ironwood Pharmaceuticals
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Obtain Report Details: http://www.transparencymarketresearch.com/constipation-treatment-market.html
Constipation treatment normally starts with lifestyle and diet changes meant to increase the speed at which stool moves through your intestines, if it doesn’t help doctors or physicians recommend medications or surgery. Lifestyle and diet change include increase in fiber intake, physical activities such as exercise to increase muscle activities in intestines and take sufficient time in bathroom, allowing enough time to have a bowel movement without felling rushed. Rising prescription opioid consumption, growing ageing population, rising healthcare expenditure, launch of targeted medicines, and growing awareness likely to drive the constipation treatment market in the forecast period. According to National Center for Biotechnology Information, over 4 million people in the United States have frequent constipation, corresponding to a prevalence of about 2 percent. Constipation was the most common digestive complaint in the United States, outnumbering all other chronic digestive conditions.
The constipation treatment market has been segmented by type, by treatment options, by method of administration, by distribution channel and by geography. In terms of type, the constipation treatment market has been categorized into chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC). The number of patients suffering from opioid induced constipation is increasing across the globe. Close to 100 Mn U.S. patients in 2013 were suffering from OIC, according to the American Academy of Pain Medicine. Based on treatment options, the constipation treatment market has been categorized into pharmacological treatment and non pharmacological treatment. Further, pharmacological treatment is segmented into bulk-forming agents, stool softeners and emollients, osmotic agents, stimulants, chloride channel activators and others. Based on method of administration, the constipation treatment market is categorized into oral and parenteral (subcutaneous injection). And based on distribution channel, constipation treatment market is categorized into drug store, independent pharmacies and hospital pharmacies.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16442
Geographically, constipation treatment market has been categorized in five regions, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America was observed to be the largest constipation treatment market owing to the large percentage of population suffers from constipation. At the moment, North America dominates in terms of opioid consumption. According to the American Society of Interventional Pain Physicians, the U.S. alone consumes close to 80% of the global supply of opioids. Europe was observed to be the second largest market in the high acuity information system, the high prevalence rates, economic cost and adverse implications on the quality of life and health state likely to drive the market in Europe. The major factor that would drive the market in Asia Pacific include the acceptance and demand for high end medical infrastructure in the region. China, Japan and India are the most developing countries in the region and hence would fuel the market growth for constipation treatment market. According to Abbott Gut-Health Survey, 14% of people in urban India suffer from chronic constipation. South American countries such as Brazil and Mexico are the regions that have significant potential for growth due to evolving medical structure, and high disposable income.
The major players operating in this market include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., Cosmo Pharmaceuticals, Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., and Ironwood Pharmaceuticals
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
No comments:
Post a Comment